Gelteq Ltd. (GELS) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Gelteq Ltd. (GELS:NASDAQ), powered by AI.

Current Price
$1.53
Sector
Healthcare
What is the Gelteq Ltd. stock price forecast?

Gelteq Ltd. is currently trading at $1.53. View real-time AI analysis on Alpha Lenz.

What is Gelteq Ltd. insider trading activity?

View the latest insider trading data for Gelteq Ltd. on Alpha Lenz.

What is Gelteq Ltd.'s P/E ratio?

View Gelteq Ltd.'s valuation metrics on Alpha Lenz.

Gelteq Ltd.

NASDAQ · GELS
$1.53+1.02(+197.09%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Gelteq Ltd.'s future dividend policy...
Alpha Chat Insight

Gelteq Ltd.'s ROE is -43.0%. Explore profitability and growth together.

Ask for details

Company Overview

Gelteq Ltd. is a biopharmaceutical company focused on developing and commercializing innovative gel-based formulations for various therapeutic applications. At its core, Gelteq specializes in transforming traditional oral and injectable medications into more convenient gel formats, potentially enhancing patient compliance and drug efficacy. The company operates within the healthcare and pharmaceuticals sector, targeting conditions that require precise dosing and improved delivery mechanisms. One of Gelteq’s notable features is its application of proprietary gel technology across a range of therapeutic areas, including pain management and chronic disease treatment. This technology can enhance drug absorption and provide alternative administration routes, offering potential benefits for both healthcare providers and patients. In the financial market, Gelteq Ltd. plays a role as a niche player in the biopharmaceutical industry, providing innovative solutions that could meet unmet medical needs. The company's focus on reformulating existing drugs can shorten development timelines and reduce risk compared to novel drug candidates, marking its significance in a competitive landscape where effective delivery solutions are increasingly valued.

CEOMr. Nathan Jacob Givoni
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees7

Company Statistics

FY 2025

Profile

N/AMarket Cap
$165.65KRevenue
0.00Shares Out
7Employees

Margins

N/AGross
-2284.45%EBITDA
-2988.98%Operating
-4011.86%Pre-Tax
-4011.86%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

3.93%Rev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-31.47%ROA
-42.99%ROE
-22.50%ROIC

Financial Health

$344.65KCash & Cash Equivalents
$5.33MNet Debt
35.88%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Gelteq Ltd. (ticker: GELS) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 7 employees.

The current price is $1.53 with a P/E ratio of -x and P/B of -x.

ROE is -42.99% and operating margin is -2988.98%. Annual revenue is $165,645.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Gelteq Ltd. (GELS) Stock Forecast 2026 $1.53 — Price, Financials & Analyst Targets | Alpha Lenz